Basilea Pharmaceutica Deutschland GmbH

Company

    • Company type:
      • Manufacturer
    • Year founded:
    • not available
    • Employees (at the site):
    • not available
    • Turnover range:
    • not available
    • Products/services:
    • Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

      Basilea has a broad pipeline of innovative drugs with well differentiated and competitive profiles to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. Basilea’s anti-infectives isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic BAL30072 and the oncology compound BAL101553 are in clinical phase I.

    • Core competencies:
    • not available

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Therapeutic drug development
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Thomas Trilling (Mr.)
      - Management